A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HMI-203 IN ENZYME REPLACEMENT THERAPY (ERT)-TREATED ADULTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) (JUMPSTART TRIAL)

Registry ID

HMI-203-101

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

HOMOLOGY MEDICINES, INC.

Start date

2023-01-20

Completion date

2023-08-08

Last update

2022-07-13

Conditions

• MUCOPOLYSACCHARIDOSIS TYPE II (MPS II)

Related clinical trials

• EFFECT OF ADALIMUMAB ON MUSCULOSKELETAL DISEASE IN MUCOPOLYSACCHARIDOSIS TYPES I, II, IVA AND VI
• AN OPEN-LABEL EXTENSION TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DNL310 IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) FROM STUDY DNLI-E-0002 OR STUDY DNLI-E-0007
• A PHASE 2/3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DNL310 VS IDURSULFASE IN PEDIATRIC PARTICIPANTS WITH NEURONOPATHIC OR NON-NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II

View on source registry